This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed NSCLC. MTB uses a team of specialists to develop a personalized treatment plan for each patient.
1 Primary · 3 Secondary · Reporting Duration: 8 weeks, 12 weeks, and 1 year
500 Total Participants · 2 Treatment Groups
Primary Treatment: Molecular tumor board assisted care · No Placebo Group · N/A
Age 18 - 120 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: